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Abstract
The b/-directional nature of the neuro vegetative symptoms of de
pression, as well as the differential response to antidepressant
medications, underscore the existence of possible subtypes of this
disorder. This study surveyed 56 physicians practicing psychiatry/n
Hawaii for opinions regarding the most effective antidepressant
medication for the following symptoms: hypersomnia vs. insomnia,
psychomotor agitation vs. retardation, and gain vs. loss of appetite
or weight. Fluoxetine was found to be the drug of choice for weight
and appetite gain, hypersomnia, and psychomotor retardation.
Mirtazapine was viewed as most effective for weight and appetite
loss. Trazodone was found most effective for insomnia and
nefazodone forpsychomotoragitation. ltis concluded thatsubtyping
of depression should be investigated at the symptom level and the
generalizabilityof the effects of each specific compound should be
tested.
The heterogeneous nature ofdepression has led to research designed
to identify subtypes based on diagnostic criteria, physiological and
biochemical markers, etiological evidence, and differences in re
sponse to treatment.‘234ldentifying differential responses to antide
pressant medications has become an important approach to subtyping
given the rapid increase in prescribing these drugs in recent years.
While there have been surveys attempting to identify factors
affecting physician choice of specific antidepressants, such as
severity ofdepression and comorbidity with anxiety,6little is known
about the relation of choice and presence of particular depressive
symptoms. 34 The purpose of the present study is to explore subtypes
in terms of prescribing habits for a subset of symptoms that differ
markedly across cases of depression, the neurovegetative symptoms
that can occur in a bi-directional manner (hypersomnia vs. insomnia,
psychomotor agitation vs. retardation, and gain vs. loss of appetite
or weight).
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It is widely accepted that the major antidepressant groups differ
entially alter several serotonergic and noradrenergic neurotransmit
ter systems, directly and indirectly, antidepressants include
monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
(TCAs), and second generation compounds (SGCs; including selec
tive serotonin reuptake inhibitors [SSRIs]). Given the potential
differential effects of antidepressants, it follows that some medica
tions would be relatively more effective with certain symptoms of
the bi-directional ones involving either an
increase or decrease in neurovegetative behaviors.
In a recent review, Mongeau et at.7 concluded agents that are 5-HT
or noradrenaline reuptake inhibitors are equally effective for treat
ment of depression, but this conclusion was based on research that
did not measure drug effects upon particular depression symptoms.
Research on the effects of different antidepressants upon atypical
depression, whose definition includes the reversal of the usual
pattern of bi-directional symptoms mentioned above, has been
mixed,89although one laboratory found the MAOI phenelzine
to be superior to the TCA imipramine.
Only a few studies have explored the effects of the newer genera
tion of antidepressants upon bi-directional symptoms.’1Equivocal
findings may be due to the following methodological limitations of
these studies: (1) use of global improvement scores to evaluate
treatment outcome, rather than measures of the effect of antidepres
sants upon each bi-directional symptom; (2) inclusion of only one
drug within the type(s) under investigation, limiting generalizability
to other compounds classified within the same type of antidepres
sant; (3) definitions of atypical depression that include not only
neurovegetative behavior, but also premorbid personality character
istics such as rejection sensitivity 8; and (4) use ofheterogeneous and
global criteria to label atypical depression that can include any two
of four symptoms, which obscures information on the precise bi
directional symptoms involved. For example, using the Columbia
criteria ‘° a case of depression could be labeled atypical if weight
gain and psychomotor retardation (severe fatigue, leaden paralysis)
are present. It would be unknown in this case if sleep was increased,
decreased, or unchanged.
Because little is known about specific antidepressant drug-symp
tom relations, the purpose of this study was to survey psychiatrists
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about their prescription habits and clinical opinion of the most
effective drug for hi-directional symptoms ofunipolar nonpsychotic
depression among adults. If physicians report symptom-specific
efficacy of particular antidepressants, these observations would
justify animal model testing and the conduct of clinical trials
designed to create specific drug-symptom profiles along the lines
proposed by Stahl.4
Method
Subjects. Participants were 56 psychiatrists practicing in Hawaii.
Their medical specialties were as follows: 37 (62%) general psy
chiatry, 2 (3%) child psychiatry, 1(2%) rehabilitative medicine, and
16 (27%) multiple psychiatric specialties. The mean age was 51.20
years (Si = 10.79) and 45 (80%) were male and 12 (20%) female.
The mean years since licensure was 21.23 ( = 11.14). Ethnicity
was 2 (3%) Pacific Islander. 1 (2%) Hawaiian-part Hawaiian, 39
(65%) Caucasian, 11(18%) Asian, 1 (2%) mixed, and 3 (5%) other.
Their employment settings included 20 (33%) private practice, 5
(8%) hospital, 1 (2%) community health center, 3 (5%) university,
3 (5%) other, and 25 (42%) multiple settings. Some participants
failed to report part of the demographic information, so percentages
do not add up to 100%.
Materials. A fourteen-item Opinion Survey on Use of Antide
pressant Medications was developed by the present investigators.
The Survey provided the respondents with the list of three MAOIs.
seven TCAs, and 12 SGCs (including SSRIs) that appear in Table 1.
Three items asked respondents to rate on a 5-point Liken scale the
frequency of prescribing each type of antidepressant for adults
presenting with unipolar nonpsychotic depression defined as major
depressive disorder. dysthymia, or depressive disorder not other
wise specified. One open-ended item asked what drug is most
frequently prescribed by the respondent. Eight open-ended items
asked the respondent to indicate the most effective medication for
the following symptoms of adult unipolar nonpsychotic depression:
weight loss, appetite loss, weight gain, appetite gain, insomnia,
hypersomnia, psychomotor agitation, and psychomotor retardation.
Two items measured diagnostic and treatment progress procedures
typically used. These could include unstructured or semi-structured
interview and mental status examination, structured interview.
clinical rating or behavioral checklist, self-report questionnaires,
and other unspecified devices. The remaining items concerned
demographic information.
Procedure. Surveys were mailed to 196 physicians with an
addressed and stamped envelop. Physicians were those known by
the Hawaii Medical Psychiatric Association to practice psychiatry
in Hawaii. Fifty-six (29%) returned the Survey within approxi
mately one month. Due to the anonymity of the survey, the differ
ences between responders and nonresponders are unknown.
Results
Because the participants’ reported opinions may have been affected
by the assessment devices they typically use, it is important to
consider these findings. In terms of establishing a diagnosis for
unipolar nonpsychotic depression, 31(52%) reported using unstruc
tured or semi-structured interview and mental status examination, 1
(2%) self-report measures, and 23 (38%) multiple devices. In tenus
of treatment progress, 30 (50%) reported using unstructured or
semi-structured interview and mental status examination, 1 (2%)
self-report measures, 1 (2%) other devices, and 22 (37%) multiple
devices.
Participants’ mean ratings on a 5-point Likert scale (1 = not at all;
5 = always) of the frequency of prescribing the three types of
antidepressants were 1.55 (S12= 0.60) for MAOIs, 3.79 (Sii= 0.76)
for SGCs, and 2.38 (SD = 0.68) for TCAs. Therefore, MAOIs were
prescribed not at all to rarely, SGCs were prescribed sometimes to
usually, and TCAs were prescribed rarely to sometimes. An ANOVA
indicated that the means were significantly different (p<.OO1).
Fisher’s post-hoc least significant difference tests indicated that
each mean was significantly different from the other two means
when considering the familywise error rate.
When asked what drug on Table I they most often prescribed. 51
(83%) respondents reported SGCs and 1 (2%) reported TCAs
(imipramine). The remaining respondents indicated multiple types
of drugs. Of the respondents reporting specific SGCs as most
commonly prescribed, 34 (52%) indicated SSRI’s (sertraline,
fluoxetine, and paroxetine). The number and percent of respondents
reporting they most often prescribe other SGCs are as follows: 2
(3%) nefazodone, 1 (2%) trazodone, and 1 (2%) venlafaxine.
In order to test whether there is an association between antidepres
sant drugs and each bi-directional symptom. Chi-square analyses of
expected versus obtained frequencies were conducted both for type
of drug and for specific drugs. The results for each symptom are
listed below and reported in Table 2. Percentages do not total to 100
due to listwise deletion of missing data.
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Table 1. Antidepressants included on the opinion survey
TRICYCLIC COMPOUNDS
Imipramine (TOFRANIL)
Desipramine (NORPRAMIN)
Trimipramine (SURMONTIL)
Protriptyline (VIVACTIL)
Nortriptyline (PAMELOR, AVENTIL)
Amitriptyilne (ELAVIL)
Doxepin (ADAPIN, SINEQUAN)
SECOND-GENERATION COMPOUNDS
Amoxapine (ASENDIN)
Maprotiline (LUDIOMIL)
Trazodone (DESYREL)
Fluoxetine (PROZAC)
Fluoxetine (LUVOX)
Bupropion (WELLBUTRIN)
Sertraline (ZOLOFT)
Paroxetine (PAXIL)
Clomipramine (ANAFRANIL)
Venlataxine (EFFEXOR)
Mirtazapine (REMERON)
Nefazodone (SERZONE)
MAO INHIBITORS
Pheneizine (NARDIL)
Isocarboxazid (MARPLAN)
Tranylcypromine (PARNATE)
Weight loss. For type of drug, 18 (30%) reported TCAs while 29
(48%) reported SGCs to be most effective (Chi-square = 73.62, df
= 2, p <001). Of the specific drugs indicated as most effective, most
(18%) reported mirtazapine (Chi-square = 16.13, df= 4, p < .003).
Weight cain. For type of drug, 2 (3%) reported TCAs while 46
(77%) reported SGCs to be most effective (Chi-square = 63.72, df
2, p <.00 1). Of the specific drugs. most (43%) reported fluoxetine
as most effective (Chi-square 61.31. df = 5, p <.001).
Appetite loss. For type ofdrug, 17(28%) reported TCAs while 30
(50%) reported SGCs to be most effective (Chi-square = 69.99, df
= 2. p <.001). Of the specific drugs, most (17%) reported mirtazapine
as most effective (Chi-square 21.67, df= 5, p <.001).
Appetite cain. For type of drug. 1 (2%) reported TCAs while 46
(77%) reported SGCs as most effective (Chi-square = 65.25, df= 2.
p <.001). Of the specific drugs, most (48%) reported fluoxetine as
most effective (Chi-square = 76.97. df= 4, p <.001).
Insomnia. For type of drug, 7 (12%) reported TCAs while 44
(73%) reported SGCs as most effective (Chi-square = 58.46, df= 2.
p <.00 1). Of the specific drugs, most (33%) reported trazodone as
most effective (Chi-square = 38.52, df= 5, p < .001).
Hypersomnia. For type of drug, 1(2%) reported TCAs, 44(73%)
reported SGCs, and 4(7%) reported MAOIs as most effective (Chi
square = 277.10, df = 3, p <.001). Of the specific drugs, most (40%)
reported fluoxetine as most effective (Chi-square 56.13, df= 5, p
<.001).
Psychomotor retardation. For type of drug, 5 (8%) reported
TCAs while 44(73%) reported SGCs as most effective tChi-square
=58.47. df= 2, p <.001). Of the specific drugs, most (38%) reported
fluoxetine as most effective (Chi-square = 41.78. f= 4. p <.001).
Psychomotor agitation. For type of drug. 13 (22%) reported
TCAs while 36(60%) reported SGCs as most effective (Chi-square
= 57.61. df = 2, p < .001). Of the specific drugs, most reported
nefazodone (22%) as most effective (Chi-square = 26.39, df = 5. p
<.001).
Discussion
The results of this survey must be viewed within the limitations of
the naturalistic survey method employed. The participants were a
convenience sample of physician volunteers whose names were on
the mailing list of the Hawaii Psychiatric Medical Association and
were not randomly selected. The differences between responders
and nonresponders to the survey are unknown due to the desire to
maintain anonymity. The survey was developed for this investiga
tion and is of unknown reliability and validity. We report aggregate
opinion data only. rather than objective case-by-case treatment and
symptom profiles and outcome measures, so our findings are subject
to reporting biases. In addition, many of the survey questions
obtained frequency data on drug-symptom relations rather than
Likert-like independent ratings in order to keep the survey brief
(ratings would have required an additional 176 questions). Finally,
we did not assess a range of patient and physician factors that could
affect prescribing habits, such as other depression symptoms. side
effects, insurance, marketing factors, past response to other drugs,
Axis II co-morbidity’2medical condition, type of psychiatric prac
tice (e.g. private or institutional), type of training (e.g., biological-
psychotherapy focus), and years of experience.
We found that the most common type of antidepressant medica
tion prescribed for unipolar nonpsychotic depression and for each
specific hi-directional neurovegetative symptom was a SGC (espe
cially SSRIs). This finding is consistent with prior investigations of
prescribing habits reporting that SSRIs were chosen most frequently
by psychiatrists for outpatient depression regardless of patients’
age, sex, race, or payment source?
Our most interesting findings concerned what particular SGC was
associated with specific hi-directional symptoms. Of the 12 SGCs to
consider, the participants reported specific neurovegetative symp
tom effects for the following four compounds: mirtazapine.
fluoxetine. trazodone. and nefazodone (see Table 2 for drug-symp
tom associations).
It is noteworthy that fluoxetine was reported as being most
effective for hypersomnia, weight and appetite gain, and psychomo
tor retardation as these symptoms constitute a partial description of
atypical depression according to the Columbia criteria.8Our find
ings are consistent with Nierenberg et. al’s call for the investigation
of the effects of SGCs upon atypical depression.” However, the
Columbia criterion requires only two of these symptoms to be
present, indicating the importance of investigating the effects of
antidepressants at the symptom level.
The prescribing habits of the psychiatrists participating in this
study indicate that clinicians tend to tailor their choices of antide
pressants at least partly based upon neurovegetative symptom
profiles. The reported antidepressant of choice varied as a function
of the direction of change in psychomotor activity, sleep. and
appetite or weight. Therefore, our findings support a subtyping or
symptom-treatment profiling approach to unipolar nonpsychotic
depression.2S4
The basis of symptom profiling by our participants of course is
unknown. One possible explanation is that the clinicians are select
ing compounds based upon what is known about the agent’s differ
ential effects upon certain serotonergic and noradrenergic neu
rotransmitter systems. For example, none of the agents in Table 2 are
considered to inhibit dopamine reuptake but they do differ in terms
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Table 2. Significant drug-symptom associations
Symptom Drug Type Specific Drugs
Weight loss SGC Mirtazapine (REMERON)
Weight gain 5GC Fluoxetine (PROZAC)
Appetite loss SGC Mirtazapine
Appetite gain 5GC Fluoxetine
Insomnia SGC Trazodone (DESYREL)
Hypersomnia 5GC Fluoxetine
Psychomotor
retardation SGC Fluoxetine
Psychomotor
agitation SGC Netazodone (SERZONE)
Note: 5GC = second generation compound; trade names for drugs are in parentheses
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of sedative activity, anticholinergic activity, inhibition of norepi
nephrine and serotonin reuptake, and blockade of serotonergic and
noradrenergic receptors.’2Another possibility for our findings is
that clinicians have also had the opportunity to observe patterns of
the therapeutic and side effects of different agents upon presenting
neurovegetative symptoms and prescribe accordingly. This symp
tom profiling would be consistent with reports of similar therapeutic
and side effects in the literature.
The reported differential effects of antidepressant agents as a
function of presenting symptoms is inconsistent with arguments that
all drugs that inhibit 5-HI reuptake are equally effective.7 The
results of this study suggest that there is a need for clinical guidelines
for the choice of specific antidepressant medications based upon the
particular presenting symptoms of unipolar nonpsychotic depres
sion.34 The findings support the investigation of animal models of
neurovegetative symptoms of depression as well as the implemen
tation of clinical trials that evaluate the generalizability of the effects
of each drug compound across type of agent and across type of
depressive symptom.
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POISON CENTER TIPS
• Keep the number of the Hawaii Poison Center on
or near your telephone.
• If you suspect a poisoning, do jp wait for signs
and symptoms to develop. Call the Hawaii Poison
Center immediately.
• Always keep Ipecac Syrup in your home. (This is
used to make a person vomit in certain types of
poisoning.) Do not use Ipecac Syrup
unless advised by the Hawaii Poison
Center.
• Store all medicines, chemicals, and household
products out of reach and out of sight, preferably
locked up.
• A good rule to teach children is to “always ask
first” before eating or drinking anything—don’t
touch, don’t smell, don’t taste.
1319 Punahou Street, Honolulu, HI 96826
OAHU: 941-4411
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